Doubling down on human epidermal growth factor receptor 2

Journal of Clinical Oncology

Volumn 30, Issue 14, 2012, Pages 1574-1576

  Krop, Ian ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; DRUG RECEPTOR BINDING; EARLY CANCER; EDITORIAL; FEMALE; HUMAN; MONOTHERAPY; ONCOGENE NEU; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; BREAST TUMOR; METABOLISM; NOTE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 84863745649     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.1463     Document Type: Editorial

References (14)

1. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
2. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
3. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005 (Pubitemid 41464706)
4. Blackwell KL, Burstein HJ, Storniolo AM, et al: Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2- positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130, 2010
5. von Minckwitz G, du Bois A, Schmidt M, et al: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 27:1999-2006, 2009
6. Konecny GE, Pegram MD, Venkatesan N, et al: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630-1639, 2006 (Pubitemid 43259947)
7. Baselga J, Bradbury I, Eidtmann H, et al: First results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010 (abstr S3-3)
8. Baselga J, Gelmon KA, Verma S, et al: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138-1144, 2010
9. Cortés J, Fumoleau P, Bianchi GV, et al: Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: Activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:1594-1600, 2012
10. Baselga J, Cortés J, Kim S-B, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
11. Gianni L: Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study ('NeoSphere'). Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010 (abstr S3-2)
12. Lee-Hoeflich ST, Crocker L, Yao E, et al: A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy. Cancer Res 68:5878-5887, 2008
13. Junttila TT, Akita RW, Parsons K, et al: Ligand-independent HER2/HER3/ PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429-440, 2009
14. Lin NU, Mayer IA, Najita JS, et al: TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC).J Clin Oncol 29:51s, 2011 (suppl; abstr 527)